|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online March 29, 2004
doi: 10.1242/10.1242/jcs.01035
Research Article |
Department of Immunology and Oncology, Centro Nacional de Biotecnología/CSIC, Universidad Autónoma de Madrid, Cantoblanco, E-28049 Madrid, Spain
* Author for correspondence (e-mail: smanes{at}cnb.uam.es)
Accepted 3 December 2003
Association of matrix metalloprotease 9 (MMP9) to the cell membrane is considered important in tumor growth and angiogenesis. To dissect this regulatory mechanism, we generated raft and non-raft MMP9 chimeras to force membrane expression in the MCF-7 human breast carcinoma cell line. MMP9 targeting to non-raft cell surface domains rendered a constitutive active membrane MMP9 form, suggesting a contribution by the lipid environment in MMP activation. We generated human breast cancer xenograft models using MCF-7 cells overexpressing secreted and membrane-anchored MMP9. The non-raft MMP9 chimera was constitutively active at the cell membrane in xenografts, but this activation did not correlate with an increase in MMP9-induced angiogenesis. Capillary number and vessel perimeter were specifically increased only in tumors overexpressing wild-type MMP9 (the secreted form); this increase was inhibited when tumors were induced in doxycycline-treated mice. Xenografts from tumor cells overexpressing wild-type MMP9 showed increased vascular endothelial growth factor (VEGF)/VEGFR2 receptor association, which was also dependent on MMP9 activity. These observations indicate that membrane location can influence MMP9 activity in vitro and in vivo, and confirm the relevance of stromal-associated, but not tumor-bound MMP9 in mediating tumor-induced angiogenesis.
Key words: Metalloprotease, Tumor growth, Angiogenesis, Lipid rafts, Membrane targeting
This article has been cited by other articles:
![]() |
E. Mira, B. Leon, D. F. Barber, S. Jimenez-Baranda, I. Goya, L. Almonacid, G. Marquez, A. Zaballos, C. Martinez-A., J. V. Stein, et al. Statins Induce Regulatory T Cell Recruitment via a CCL1 Dependent Pathway J. Immunol., September 1, 2008; 181(5): 3524 - 3534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Redondo-Munoz, E. Ugarte-Berzal, J. A. Garcia-Marco, M. H. del Cerro, P. E. Van den Steen, G. Opdenakker, M. J. Terol, and A. Garcia-Pardo {alpha}4{beta}1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells Blood, July 1, 2008; 112(1): 169 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sun, S. Zhang, D. Zhang, X. Yin, S. Wang, Y. Gu, and Y. Wang Doxycycline Influences Microcirculation Patterns in B16 Melanoma Experimental Biology and Medicine, November 1, 2007; 232(10): 1300 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kong, Y. Li, Z. Wang, S. Banerjee, and F. H. Sarkar Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-{kappa}B Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer Cancer Res., April 1, 2007; 67(7): 3310 - 3319. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, K. Furukawa, H.-H. Chen, T. Sakakibara, T. Urano, and K. Furukawa Metastatic Potential of Mouse Lewis Lung Cancer Cells Is Regulated via Ganglioside GM1 by Modulating the Matrix Metalloprotease-9 Localization in Lipid Rafts J. Biol. Chem., June 30, 2006; 281(26): 18145 - 18155. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Rao, C. Gondi, C. Chetty, S. Chittivelu, P. A. Joseph, and S. S. Lakka Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells Mol. Cancer Ther., September 1, 2005; 4(9): 1399 - 1408. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Fernandez, L. Yan, G. Louis, J. Yang, J. L. Kutok, and M. A. Moses The Matrix Metalloproteinase-9/Neutrophil Gelatinase-Associated Lipocalin Complex Plays a Role in Breast Tumor Growth and Is Present in the Urine of Breast Cancer Patients Clin. Cancer Res., August 1, 2005; 11(15): 5390 - 5395. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Reich, Y. Katz, R. Hadar, and E. Breuer Carbamoylphosphonate Matrix Metalloproteinase Inhibitors 3: In vivo Evaluation of Cyclopentylcarbamoylphosphonic Acid in Experimental Metastasis and Angiogenesis Clin. Cancer Res., May 15, 2005; 11(10): 3925 - 3929. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF] |
||||